Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial

BACKGROUND: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. METHODS: A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Chest
Autores principales: Silvestri, Gerard A., Tanner, Nichole T., Kearney, Paul, Vachani, Anil, Massion, Pierre P., Porter, Alexander, Springmeyer, Steven C., Fang, Kenneth C., Midthun, David, Mazzone, Peter J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American College of Chest Physicians 2018
Materias:
Lung Cancer
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6689113/
https://ncbi.nlm.nih.gov/pubmed/29496499
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.chest.2018.02.012
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares